Actionable news
All posts from Actionable news
Actionable news in KITE: KITE PHARMA Inc,

Kite (KITE) Q2 Earnings: What's in Store for the Stock?

Kite Pharma, Inc. KITE is scheduled to report second-quarter 2016 results on Aug 8, after the market closes. The company, which started trading from Jun 2014, posted a positive earnings surprise in the last quarter. Let's see how things are shaping up for this announcement.

Factors at Play

Kite Pharma, a development-stage biopharmaceutical company, is looking to transform the paradigm of treating cancer which involves using the body’s immune system to recognize and destroy cancer cells. The company uses its engineered autologous cell therapy (eACT) to genetically modify T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). These modified T-cells are designed to recognize and destroy cancer cells.

Kite Pharma’s revenues comprise the amortization of deferred collaboration revenues related to the $60 million upfront payment received under its collaboration agreement with Amgen, Inc. AMGN in the first quarter of 2015.

With no approved products in its portfolio, investor focus will be primarily on the company’s cash burn and pipeline updates.

At the time of releasing first quarter results, Kite had guided towards 2016 net cash burn of $235 - $250 million and net loss of $295 -...